Expanding the ImmTAX Platform to Gamma Delta T Cell Targets
Time: 11:45 am
day: Conference Day One - Track B
Details:
- Introduction to the Immunocore ImmTAX platform and the first approved TCR bi-specific therapeutic.
- Establishment of a γδ TCR discovery platform
- Development of an affinity enhanced γδ TCR
